Gene therapy developer Renovacor, a Temple University spinout, has secured series A funding from investors including Novartis Venture Fund.
Renovacor, a US-based gene therapy spinout of Temple University focused on cardiovascular disease, closed an $11m series A round yesterday co-led by Novartis Venture Fund, the corporate venturing vehicle for drug maker Novartis.
Broadview Ventures, a cardiovascular-focused impact investment unit formed by family office Leducq Family Trust, and BioAdvance co-led the round, with contributions from New Leaf Venture Partners and Innogest Capital.
Renovacor is commercialising a drug for dilated cardiomyopathy (DCM), a serious blood circulation impairment that arises…
